New recombinant human growth hormone sustained-release microcapsules successfully developed
Recently, it was learned from the Institute of Process Engineering of the Chinese Academy of Sciences that a team led by researcher Ma Guanghui developed a recombinant human growth hormone sustained-release microcapsule with uniform particle size. The relevant results were published in the international academic journal "Molecular Pharmacy".
It is understood that recombinant human growth hormone (rhGH) is widely used in the treatment of a variety of diseases such as short stature, severe burns, and fat metabolism disorders in AIDS patients. However, rhGH has a short half-life and must be injected frequently to achieve an effective blood concentration, which results in poor patient compliance.
In response to this problem, scientists have done a lot of research on rhGH sustained-release microcapsules, but there are still widespread problems such as uneven particle size of microcapsules, inability to sustain release, and poor drug stability. At the same time, the acidic products produced by the traditional hydrophobic material microcapsules during the degradation process cause inflammation at the injection site and cause serious side reactions. Therefore, the development of safe and effective rhGH sustained-release microcapsules has important research significance.
The Ma Guanghui team first used the W/O/W double emulsion method to load rhGH into the amphiphilic material polylactic acid-polyethylene glycol copolymer emulsion, and combined with the rapid membrane emulsification technology to achieve the uniformity of the microsphere size. . Subsequent in vivo rat model experiments showed that the preparation can effectively prolong the release of rhGH in vivo, and maintain the activity of rhGH well, and the bone growth of rats is obvious, which improves the therapeutic effect. In addition, compared with the conventional polylactic acid (PLA) and polylactic acid-glycolic acid copolymer (PLGA) microcapsules, the preparation does not produce an inflammatory reaction and has no effect on major organ functions such as heart, liver and kidney, and is a kind of Safe sustained release carrier.
The research was funded by the “973” project and the National Natural Science Foundation.
The first integrated protein assembly line of bacteria